Can a personalized disease-in-a-dish improve a pancreatitis patient’s therapeutic path

Salk News

June 30, 2026

Can a personalized disease-in-a-dish improve a pancreatitis patient's therapeutic path?

Salk Institute scientists develop platform to generate patient-derived organoids that can be used to study pathogenesis and identify treatment strategies in chronic pancreatitis

June 30, 2026

• Highlights
• Chronic pancreatitis, which affects around three million people worldwide, is especially difficult to treat because the molecular drivers of the disease vary from patient to patient
• Salk researchers have created a new platform for studying chronic pancreatitis that retains patient-specific disease biology
• The platform can be used to develop personalized chronic pancreatitis treatments and has already pinpointed a protein that could be a promising target for many patients

LA JOLLA-Around three million people worldwide struggle with chronic pancreatitis, a condition wherein the pancreas becomes inflamed, scarred, and painful. There is no cure for chronic pancreatitis, and it is difficult to alter the disease trajectory after onset.

Victoria Osorio-Vasquez (left) and Dannielle Engle (right) develop a platform to generate patient-derived organoids that can be used to study pathogenesis and identify treatment strategies in chronic pancreatitis.
Click here for a high-resolution image.
Credit: Salk Institute

Salk scientists are hoping to change that. In a new study published in Cell Stem Cell on June 30, 2026, the researchers developed a patient-derived organoid platform to uncover how chronic pancreatitis develops at the molecular level and identify possible therapeutic strategies. The platform hinges on organoid technology: miniature organs-in this case, from the pancreas-grown from patient-derived cells that mimic their real-life counterparts.

Using their new platform, the Salk team generated 37 organoids from patients who developed chronic pancreatitis spontaneously, from genetic factors, or other causes. The organoids revealed consistent dysfunction in the protein cystic fibrosis transmembrane conductance regulator (CFTR), which may be a future effective therapeutic target.

"Though patients can have the same clinical diagnosis of chronic pancreatitis, they can have very different underlying molecular drivers of that disease, which makes treatment especially difficult," says senior author Dannielle Engle, PhD, assistant professor and Helen McLoraine Developmental Chair at Salk. "Our work breaks down a major barrier in the field by establishing an experimental model that preserves patient-specific disease biology and can be used to develop tailored therapies."

What insights can organoids provide about chronic pancreatitis?

Thanks to patient donors, the researchers were able to generate 37 patient-derived organoid lines, spanning causes from spontaneous to alcohol-related to hereditary. Each organoid was validated to match the original patient tissue, with key molecules, proteins, and inflammatory factors present.

They surveyed the molecular signatures in each organoid and found three subtypes of chronic pancreatitis. This biology-based stratification of patients may be a better way to classify patients and determine optimal treatment, as opposed to current strategies that base care on the cause of onset.

A human pancreas tissue section with markers (red, orange, green, pink) of different chronic pancreatitis subtypes identified by the Salk Institute team.
Click here for a high-resolution image.
Credit: Salk Institute

Additionally, the team was surprised to find that approximately half of the organoids had dysfunctional CFTR.

"And CFTR dysfunction was not limited to patients with inherited CFTR mutations, suggesting that functional testing may identify therapeutic opportunities that would be missed by genetic testing alone," Osorio-Vasquez says.

There already exists a range of CFTR modulator therapies, which were developed for patients with cystic fibrosis. But the Salk team's findings suggest that these same therapies may offer pancreatic benefits. The researchers tested clinically available CFTR modulators and found they could, in fact, stabilize or restore CFTR function and reduce inflammatory signaling in responsive pancreas organoids. This small success paves the way for follow-up clinical trials.

Additional authors and funding

Other authors include Jonathan Zhu, Jan Lumibao, Kristina Peck, McKenna Stamp, Shira Okhovat, Satoshi Ogawa, Casie Kubota, Vasiliki Pantazopoulou, Kassidy Curtis, Kahing Kuo, Yang Dai, Angelica Rock, Chelsea Bottomley, Ethan Thomas, Araceli Herrera Morales, Alexandra Fowler, T'Onj McGriff, Garrett Evensen, April Williams, Michael Downes, and Ronald Evans of Salk; Kathryn Lande of Salk and Sanford Burnham Prebys; Hyemin Song and Jasper Hsu of Salk and UC San Diego; Siri Larsen, Muhamad Abdulla, and Melena Bellin of University of Minnesota; Phil Greer and Jessica Gibson of Ariel Precision Medicine; Andrew Lowy, Jingjing Zou, Alfredo Molinolo, Rebekah White, and Herve Tiriac of UC San Diego; David Whitcomb of Ariel Precision Medicine and University of Pittsburgh; and Tae Gyu Oh of University of Oklahoma.

The work was supported by the National Institutes of Health (T32CA009370, T32CA0093790, NCI CCSG: P30CA01495, NlA P30 AG068635, CCSG P30CA23100, NCI P01 CA265762), Howard and Maryam Newman Family Foundation, Helmsley Charitable Trust, Waitt Foundation, Chapman Foundation, Mission Cure Capital, LLC, Lustgarten Foundation, Conrad Prebys Foundation, Paul M. Angell Family Foundation, and Curebound (20DG11).

Written by Isabella Davis

DOI: 10.1016/j.stem.2026.06.002